Humacyte (HUMA) Competitors $2.34 -0.15 (-6.02%) Closing price 04:00 PM EasternExtended Trading$2.30 -0.04 (-1.71%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA vs. CVAC, CRMD, CMRX, CDMO, CRON, PRAX, NRIX, XERS, BCAX, and OCSShould you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), Praxis Precision Medicines (PRAX), Nurix Therapeutics (NRIX), Xeris Biopharma (XERS), Bicara Therapeutics (BCAX), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Humacyte vs. CureVac CorMedix Chimerix Avid Bioservices Cronos Group Praxis Precision Medicines Nurix Therapeutics Xeris Biopharma Bicara Therapeutics Oculis Humacyte (NASDAQ:HUMA) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability. Which has more volatility and risk, HUMA or CVAC? Humacyte has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Is HUMA or CVAC more profitable? CureVac has a net margin of 20.72% compared to Humacyte's net margin of 0.00%. CureVac's return on equity of 21.98% beat Humacyte's return on equity.Company Net Margins Return on Equity Return on Assets HumacyteN/A -942.81% -93.82% CureVac 20.72%21.98%15.72% Which has preferable valuation and earnings, HUMA or CVAC? Humacyte has higher earnings, but lower revenue than CureVac. Humacyte is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHumacyte$517K702.09-$110.78M-$0.69-3.39CureVac$535.18M1.63-$281.58M$0.824.76 Do institutionals & insiders have more ownership in HUMA or CVAC? 44.7% of Humacyte shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 5.1% of Humacyte shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend HUMA or CVAC? Humacyte presently has a consensus target price of $11.71, suggesting a potential upside of 400.61%. CureVac has a consensus target price of $14.00, suggesting a potential upside of 258.97%. Given Humacyte's higher possible upside, research analysts plainly believe Humacyte is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00CureVac 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor HUMA or CVAC? Humacyte received 16 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 71.67% of users gave Humacyte an outperform vote while only 56.25% of users gave CureVac an outperform vote. CompanyUnderperformOutperformHumacyteOutperform Votes4371.67% Underperform Votes1728.33% CureVacOutperform Votes2756.25% Underperform Votes2143.75% Does the media favor HUMA or CVAC? In the previous week, Humacyte had 10 more articles in the media than CureVac. MarketBeat recorded 14 mentions for Humacyte and 4 mentions for CureVac. Humacyte's average media sentiment score of 0.55 beat CureVac's score of 0.30 indicating that Humacyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryHumacyte beats CureVac on 11 of the 18 factors compared between the two stocks. Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HUMA vs. The Competition Export to ExcelMetricHumacyteBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$362.98M$2.93B$5.37B$8.38BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.7530.5026.8419.71Price / Sales702.09400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book18.003.286.794.50Net Income-$110.78M-$72.17M$3.23B$248.18M7 Day Performance25.13%4.28%4.07%1.14%1 Month Performance61.38%7.62%12.52%15.20%1 Year Performance-66.71%-28.15%16.83%6.56% Humacyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HUMAHumacyte2.3029 of 5 stars$2.34-6.0%$11.71+400.6%-64.7%$362.98M$517,000.00-1.75150Analyst RevisionCVACCureVac3.7187 of 5 stars$3.62+4.3%$14.00+286.7%+25.9%$812.10M$535.18M6.58880News CoverageUpcoming EarningsGap DownCRMDCorMedix2.1004 of 5 stars$11.86+1.7%$15.00+26.5%+153.9%$804.40M$82.55M-14.6430Positive NewsCMRXChimerix0.5614 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastCDMOAvid Bioservices0.8126 of 5 stars$12.50+0.1%$12.25-2.0%+34.6%$799.18M$139.91M-5.23320High Trading VolumeCRONCronos Group1.015 of 5 stars$2.05+3.5%$3.50+70.7%-24.8%$790.08M$117.62M-15.77450Positive NewsHigh Trading VolumePRAXPraxis Precision Medicines3.1765 of 5 stars$38.42+0.2%$116.50+203.2%-11.8%$782.58M$8.12M-3.73110Positive NewsNRIXNurix Therapeutics2.4113 of 5 stars$10.18+7.2%$30.44+199.1%-37.4%$776.08M$56.42M-3.52300News CoveragePositive NewsGap DownXERSXeris Biopharma4.5715 of 5 stars$4.95-1.2%$6.25+26.3%+147.8%$774.11M$203.07M-11.00290Positive NewsBCAXBicara Therapeutics1.6591 of 5 stars$14.19+9.4%$32.43+128.5%N/A$773.87MN/A0.0032Positive NewsAnalyst RevisionGap UpOCSOculis2.4273 of 5 stars$17.60-5.3%$31.50+79.0%+47.9%$768.45M$980,000.00-9.122 Related Companies and Tools Related Companies CVAC Competitors CRMD Competitors CMRX Competitors CDMO Competitors CRON Competitors PRAX Competitors NRIX Competitors XERS Competitors BCAX Competitors OCS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HUMA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
